Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weierkang pills plus triple therapy for Helicobacter pylori infection
ChiCTR2000030775Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of weierkang pills in Helicobacter pylori infection (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Hp eradication rate and Incidence of adverse reactions. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
weierkang pills
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2000030775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030775.